Late Breaking Poster Shows a Novel Oral Insulin Sensitizer Azemiglitazone (MSDC-0602K) Could Substantially Preserve Lean Muscle in Combination with Weight-Loss GLP1s
June 05, 2024 10:48 ET
|
Cirius Therapeutics
Azemiglitazone (MSDC-0602K) working through a newly identified mitochondrial target adds cardiometabolic benefit to GLP-1 receptor agonists Benefit includes preservation of lean muscle, which could...
HeartFlow AI Plaque Analysis Achieves Major Milestone Towards Medicare Coverage
June 03, 2024 12:00 ET
|
HeartFlow Holding, Inc.
HeartFlow AI Plaque Analysis Achieves Major Milestone Towards Medicare Coverage
Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024
May 31, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – May 31, 2024 Idorsia Ltd (SIX: IDIA) today announced that data from the Phase 3 study of aprocitentan, Idorsia’s endothelin receptor antagonist, will be presented by Prof....
Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024
May 31, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – May 31, 2024 Idorsia Ltd (SIX: IDIA) today announced that data from the Phase 3 study of aprocitentan, Idorsia’s endothelin receptor antagonist, will be presented by Prof....
Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
May 29, 2024 16:01 ET
|
BridgeBio Pharma, Inc.
- Acoramidis treatment resulted in increased serum transthyretin (TTR) levels by Day 28 that were sustained and were correlated with a reduced risk of all-cause mortality (ACM), cardiovascular...
Euroseas Ltd. Reports Results for the Quarter Ended March 31, 2024 and Declares Quarterly Common Stock Dividend
May 23, 2024 08:42 ET
|
Euroseas
ATHENS, Greece, May 23, 2024 (GLOBE NEWSWIRE) -- Euroseas Ltd. (NASDAQ: ESEA, the “Company” or “Euroseas”), an owner and operator of container carrier vessels and provider of seaborne transportation...
EuroDry Ltd. Reports Results for the Quarter Ended March 31, 2024
May 21, 2024 08:30 ET
|
EuroDry Ltd.
ATHENS, Greece, May 21, 2024 (GLOBE NEWSWIRE) -- EuroDry Ltd. (NASDAQ: EDRY, the “Company” or “EuroDry”), an owner and operator of drybulk vessels and provider of seaborne transportation for drybulk...
Euroseas Ltd. Sets Date for the Release of First Quarter 2024 Results, Conference Call and Webcast
May 20, 2024 16:05 ET
|
Euroseas
ATHENS, Greece, May 20, 2024 (GLOBE NEWSWIRE) -- Euroseas Ltd. (NASDAQ: ESEA), an owner and operator of container carrier vessels and provider of seaborne transportation for containerized cargoes,...
Volta Medical presents results from the first transatlantic randomized controlled trial comparing AI-assisted ablation procedure with the conventional treatment for persistent atrial fibrillation patients
May 20, 2024 08:00 ET
|
Volta Medical
TAILORED-AF trial findings demonstrated superiority in freedom from atrial fibrillation (AF) with or without anti-arrhythmic drugs at 12 months from a tailored cardiac ablation guided by artificial...
EuroDry Ltd. Sets Date for the Release of First Quarter 2024 Results, Conference Call and Webcast
May 17, 2024 09:00 ET
|
EuroDry Ltd.
ATHENS, Greece, May 17, 2024 (GLOBE NEWSWIRE) -- EuroDry Ltd. (NASDAQ: EDRY, the “Company” or “EuroDry”), an owner and operator of drybulk vessels and provider of seaborne transportation for drybulk...